Table 3.
Adverse events | CT-P10 (n = 102) | RTX (n = 51) |
---|---|---|
Any adverse event | 73 (71.6) | 43 (84.3) |
Infusion-related reaction | 20 (19.6) | 10 (19.6) |
Infection | 39 (38.2) | 21 (41.2) |
Malignancy | 0 | 1 (2.0) |
Study drug discontinuation due to adverse event | 6 (5.9) | 4 (7.8) |
Any serious adverse event | 14 (13.7) | 7 (13.7) |
Data are presented as n (%)
RTX innovator rituximab
aAll patients who received at least one (full or partial) dose of CT-P10 or RTX